Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is moving its lead candidate ONC010 from molecule to medicine, announcing key advancements in manufacturing, preclinical characterization, and clinical planning. The company has successfully produced a 300-gram development batch of ONC010's active ingredient with approximately 99.3% purity, a critical step toward scalable production. Additionally, a newly identified non-tin catalyst could improve impurity control in future polymer manufacturing, addressing a common challenge in nanoparticle-based drug delivery.
ONC010 targets Polynucleotide Kinase Phosphatase (PNKP), an enzyme involved in DNA damage repair. By inhibiting PNKP, ONC010 aims to disable cancer cells' ability to repair damage caused by chemotherapy or radiation, potentially enhancing treatment efficacy. This approach falls within the broader field of DNA Damage Response (DDR) inhibition, which has become a promising area in oncology.
The company is now building an Australian regulatory pathway for a potential First-in-Human study, with plans to advance bioanalytical, metabolism, ADME, toxicology, biodistribution, and regulatory preparation during the second half of 2026. These steps are essential for transitioning from preclinical development to clinical trials.
According to the company's latest update, these milestones collectively de-risk the development of ONC010 and position it for regulatory filing. The high purity of the API batch is particularly noteworthy, as it demonstrates the feasibility of manufacturing at a scale sufficient for clinical studies.
The focus on PNKP inhibition is part of a growing trend in precision oncology, where treatments are designed to exploit specific vulnerabilities in cancer cells. By targeting DNA repair mechanisms, ONC010 could offer a new therapeutic option for patients with tumors that are resistant to conventional therapies.
Onco-Innovations is a preclinical-stage company dedicated to developing innovative cancer therapies. Its lead candidate, ONC010, combines a small-molecule PNKP inhibitor with a nanoparticle delivery system, which may improve drug stability and targeted delivery.
The announcement comes as the company prepares for its next phase of development, with the Australian clinical pathway representing a strategic move to expedite entry into human trials. The company's progress on multiple fronts—manufacturing, analytical development, and regulatory planning—demonstrates a comprehensive approach to advancing ONC010 toward the clinic.
For more information about Onco-Innovations and its pipeline, visit the company's newsroom at ibn.fm/ONNVF.
